Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.71 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.71 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.63 |
| ▸ | IL1RN | P18510 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852031 | 1.00 | ERAP1 (0.71) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL30833613 | 1.00 | ERAP1 (0.71) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL30010303 | 0.97 | ERAP1 (0.68) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29577129 | 0.97 | ERAP1 (0.68) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29577668 | 0.97 | ERAP1 (0.68) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29577971 | 0.96 | OPRM1 (0.67) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29578343 | 0.96 | OPRM1 (0.67) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29577215 | 0.96 | OPRM1 (0.67) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL29578349 | 0.96 | OPRM1 (0.67) | ERAP1ERAP2LNPEPOPRM1OPRD1 | |
| SCHEMBL21641796 | 0.96 | ERAP1 (0.66) | ERAP1ERAP2LNPEPOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2025067293-A1 | HELICASE AND USE THEREOF | 北京齐碳科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119709689-A | Helicase and application thereof | 北京齐碳科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| CN-115073550-B | Dipeptide difunctional small molecule compound for activating enzyme catalytic reaction and application thereof | 中国科学院青岛生物能源与过程研究所 | 2024-10-08 | — | — | CN | claimed |
| CN-116789734-A | Oligopeptide group extracted from crayfish shells, extraction method and application thereof | 奇明达(北京)植物药物技术开发有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) | 2022-12-08 | — | — | US | claimed |
| CN-115397836-A | Novel antibacterial peptide and application thereof | 安尼根有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3980439-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | Szegedi Tudományegyetem (HU) | 2022-04-13 | — | — | EP | claimed |
| CN-101747410-B | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2013-03-13 | — | — | CN | claimed |
| CN-101747410-A | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2010-06-23 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| CN-101747410-B | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2013-03-13 | — | — | CN | disclosed |
| CN-101747410-A | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2010-06-23 | — | — | CN | disclosed |
| CN-101747410-A | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2010-06-23 | — | — | CN | disclosed |
| CN-101747410-A | Aminoacyl tyrosyl tryptophan tripeptide with easing pain activity and preparation method and application thereof | UNIV BEIJING | 2010-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | ERAP1 771/4885ERAP2 526/4885LNPEP 339/4885 |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | MARCKS, SORT1, PICALM | ERAP1 945/4885ERAP2 1324/4885LNPEP 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.